Micronized Antibodies in Polymeric Particles for Drug Delivery

ChangeBridge: Patent Apps - Peptides (C07K)

Published April 2nd, 2026

Detected April 2nd, 2026

Summary

USPTO published patent application US20260090991A1 for pharmaceutical compositions containing micronized antibodies encapsulated in polymeric particles. The inventors (Mathiowitz, Azagury, Baptista) disclose formulations designed to minimize initial burst release of antibodies. Compositions are formulated for oral, subcutaneous, or percutaneous administration for antibody-based therapies.

View original document View source feed page

What changed

The USPTO published a patent application (US20260090991A1) for compositions and methods of delivering large proteins via micronized antibodies encapsulated in polymeric particles. The application covers pharmaceutical formulations using specific polymer types, molecular weights, and antibody loadings to achieve minimal to no initial burst release. The compositions are designed for oral, subcutaneous, or percutaneous administration for antibody-based treatment regimens.

This is a published patent application, not a regulatory rule or guidance. No compliance actions are required from regulated entities. Companies developing antibody delivery systems may wish to review the claims to assess potential IP implications for their own R&D programs. The application was filed October 3, 2023, under Application No. 19115269.

Source document (simplified)

← USPTO Patent Applications

COMPOSITIONS AND METHODS OF DELIVERING LARGE PROTEINS

Application US20260090991A1 Kind: A1 Apr 02, 2026

Inventors

Edith MATHIOWITZ, Aharon AZAGURY, Cameron BAPTISTA

Abstract

Disclosed are pharmaceutical compositions containing micronized antibodies encapsulated and/or dispersed in polymeric particles for antibody delivery. The judicious identification of (i) a subset of polymers, (ii) polymers with certain average molecular weights, (iii) a subset of antibody loadings, and/or (iv) pre-loading antibody processing, leads to formation of polymeric particles that possess minimal to no initial burst release of micronized antibody at zero time point. The pharmaceutical compositions are formulated for oral, subcutaneous, or percutaneous administration, and are particularly suited for treatment regimens that involve antibody-based therapy.